- Home
- ETON vs IKNA Comparison
ETON vs IKNA Comparison
Compare ETON & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- IKNA
- Stock Information
- Founded
- ETON 2017
- IKNA 2016
- Country
- ETON United States
- IKNA United States
- Employees
- ETON N/A
- IKNA N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ETON Health Care
- IKNA Health Care
- Exchange
- ETON Nasdaq
- IKNA Nasdaq
- Market Cap
- ETON 199.5M
- IKNA 83.0M
- IPO Year
- ETON 2018
- IKNA 2021
- Fundamental
- Price
- ETON $8.82
- IKNA $1.68
- Analyst Decision
- ETON Strong Buy
- IKNA Buy
- Analyst Count
- ETON 3
- IKNA 2
- Target Price
- ETON $12.00
- IKNA $3.00
- AVG Volume (30 Days)
- ETON 214.1K
- IKNA 41.6K
- Earning Date
- ETON 11-11-2024
- IKNA 11-07-2024
- Dividend Yield
- ETON N/A
- IKNA N/A
- EPS Growth
- ETON N/A
- IKNA N/A
- EPS
- ETON N/A
- IKNA N/A
- Revenue
- ETON $31,381,000.00
- IKNA $1,844,000.00
- Revenue This Year
- ETON $19.61
- IKNA N/A
- Revenue Next Year
- ETON $35.39
- IKNA N/A
- P/E Ratio
- ETON N/A
- IKNA N/A
- Revenue Growth
- ETON 8.14
- IKNA N/A
- 52 Week Low
- ETON $3.03
- IKNA $1.02
- 52 Week High
- ETON $8.66
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- ETON 76.07
- IKNA 51.57
- Support Level
- ETON $7.58
- IKNA $1.68
- Resistance Level
- ETON $8.66
- IKNA $1.78
- Average True Range (ATR)
- ETON 0.42
- IKNA 0.04
- MACD
- ETON -0.07
- IKNA 0.00
- Stochastic Oscillator
- ETON 91.49
- IKNA 36.36
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.